<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/379j–72" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/379j–72/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/379j–72/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_379j_72"><akn:num>379j–72</akn:num><akn:heading>Authority to assess and use OTC monograph fees</akn:heading><akn:content><akn:p>§ 379j–72. Authority to assess and use OTC monograph fees(a) Types of feesBeginning with fiscal year 2021, the Secretary shall assess and collect fees in accordance with this section as follows:(1) Facility fee(A) In general(i) Assessment of feesEach person that owns a facility identified as an OTC monograph drug facility at any time during the applicable period specified in clause (ii) for a fiscal year shall be assessed an annual fee for each such facility as determined under subsection (c).


(ii) Applicable periodFor purposes of clause (i), the applicable period is—(I) for fiscal year 2026, the 12-month period ending on December 31, 2025;

(II) for fiscal year 2027, the 9-month period ending on September 30, 2026; and

(III) for fiscal year 2028 and each subsequent fiscal year, the 12-month period ending on September 30 of the preceding fiscal year.



(B) Exceptions(i) Facilities that cease activitiesA fee shall not be assessed under subparagraph (A) if the identified OTC monograph drug facility—(I) has ceased all activities related to OTC monograph drugs prior to—(aa) for purposes of fiscal year 2026, January 1, 2025;

(bb) for purposes of fiscal year 2027, January 1, 2026; and

(cc) for purposes of fiscal year 2028 and each subsequent fiscal year, October 1 of the preceding fiscal year; and


(II) has updated its registration to reflect such change under the requirements for drug establishment registration set forth in section 360 of this title.


(ii) Contract manufacturing organizationsThe amount of the fee for a contract manufacturing organization facility shall be equal to two-thirds of the amount of the fee for an OTC monograph drug facility that is not a contract manufacturing organization facility.



(C) AmountThe amount of fees established under subparagraph (A) shall be established under subsection (c).


(D) Due date(i) Fiscal year 2026For fiscal year 2026, the facility fees required under subparagraph (A) shall be due on the later of—(I) the first</akn:p></akn:content><akn:subsection eId="subsec_379j_72_a"><akn:num>(a)</akn:num><akn:heading>Types of fees</akn:heading><akn:content><akn:p>(a) Types of fees Beginning with fiscal year 2021, the Secretary shall assess and collect fees in accordance with this section as follows:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_72_b"><akn:num>(b)</akn:num><akn:heading>Fee revenue amounts</akn:heading><akn:content><akn:p>(b) Fee revenue amounts</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_72_c"><akn:num>(c)</akn:num><akn:heading>Adjustments; annual fee setting</akn:heading><akn:content><akn:p>(c) Adjustments; annual fee setting</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_72_d"><akn:num>(d)</akn:num><akn:heading>Identification of facilities</akn:heading><akn:content><akn:p>(d) Identification of facilities Each person that owns an OTC monograph drug facility shall submit to the Secretary the information required under this subsection each year. Such information shall, for each fiscal year—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_72_e"><akn:num>(e)</akn:num><akn:heading>Effect of failure to pay fees</akn:heading><akn:content><akn:p>(e) Effect of failure to pay fees</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_72_f"><akn:num>(f)</akn:num><akn:heading>Crediting and availability of fees</akn:heading><akn:content><akn:p>(f) Crediting and availability of fees</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_72_g"><akn:num>(g)</akn:num><akn:heading>Collection of unpaid fees</akn:heading><akn:content><akn:p>(g) Collection of unpaid fees In any case where the Secretary does not receive payment of a fee assessed under subsection (a) within 30 calendar days after it is due, such fee shall be treated as a claim of the United States Government subject to subchapter II of chapter 37 of title 31.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_72_h"><akn:num>(h)</akn:num><akn:heading>Construction</akn:heading><akn:content><akn:p>(h) Construction This section may not be construed to require that the number of full-time equivalent positions in the Department of Health and Human Services, for officers, employers, and advisory committees not engaged in OTC monograph drug activities, be reduced to offset the number of officers, employees, and advisory committees so engaged.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>